ADVANCED NET OF GI ORIGIN

Clinical trials for ADVANCED NET OF GI ORIGIN explained in plain language.

Never miss a new study

Get alerted when new ADVANCED NET OF GI ORIGIN trials appear

Sign up with your email to follow new studies for ADVANCED NET OF GI ORIGIN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug AUR103 calcium targets Hard-to-Treat neuroendocrine tumors

Disease control Not yet recruiting

This phase 2 study tests a new drug, AUR103 calcium, in 30 adults with advanced neuroendocrine tumors that have worsened after at least one prior treatment. Participants take the drug twice daily until their disease gets worse or side effects become too severe. The main goal is t…

Matched conditions: ADVANCED NET OF GI ORIGIN

Phase: PHASE2 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control

Last updated Jun 12, 2026 12:03 UTC

ADVANCED NET OF GI ORIGIN

Get alerted when new ADVANCED NET OF GI ORIGIN trials appear

New drug AUR103 calcium targets Hard-to-Treat neuroendocrine tumors